Navigation Links
Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/21/2007

rrently available drugs.

"Assessment of In Vitro Activity of Cethromycin Against Strains of Haemophilus Influenzae"

Cethromycin demonstrated potent in vitro activity against all Haemophius influenzae isolates studied regardless of beta-lactamase status. Based on the MIC data, cethromycin potency was comparable to telithromycin and azithromycin, and was superior to clarithromycin. These findings demonstrate that cethromycin has the potential to be a potent therapeutic option for the treatment of CAP caused by Haemophilus influenzae.

The following poster presentations demonstrated the potency of cethromycin as a potential treatment against bioterrorism pathogens:

"Efficacy of Cethromycin Against a Lethal Inhalation Anthrax Challenge in Rhesus Macaques"

All antibiotic treated animals maintained normal hematologic parameters and remained abacteremic throughout the treatment period. All cethromycin- treated animals survived, with only 1/10 demonstrating abnormal hematologic parameters following antibiotic cessation. One ciprofloxacin-treated animal demonstrated clinical signs of infection, bacteremia, alterations in hematologic and coagulation parameters, and died nine days after cessation of antibiotic treatments. All 10 control monkeys demonstrated a combination of clinical signs of anthrax, bacteremia, and/or alterations in hematologic and coagulation parameters post-challenge with five of ten succumbing to the infection. This study demonstrated that a thirty day course of oral cethromycin was 100% protective against a lethal dose of inhaled Bacillus anthracis Ames strain spores.

"Antimicrobial Activity of Cethromycin, a Novel Ketolide, Tested Against a Diverse Collection of Francisella Tularensis Strains"

Cethromycin was efficacious against 30 Francisella tularensis strains. Cethromycin had significant in vitro activity against Francisella tularensis. Cethromycin preferentially accumulates in the alveolar cells of the lungs,
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Managing Preanalytical Processes for Patient Safety
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... N.J. , July 25, 2014  Acsis ... brand protection and serialization solutions, has recently posted ... that addresses current and future needs for ... for the old supply chain model no longer ... in technology, including the growth of mobile technology, ...
(Date:7/25/2014)...  IDEXX Laboratories, Inc. (NASDAQ: IDXX ) ... 2014 increased 11% versus the prior year period to ... second quarter of 2014 versus the prior year period ... inventory 2 . Earnings per diluted share ("EPS") for ... the prior year period to $1.10."In the second quarter, ...
(Date:7/25/2014)... 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... and report second quarter 2014 financial results before the ... 2014. That same day, Arena will host a conference ... a.m. Pacific Time). The conference call ... and 914.495.8552 for international callers. Please specify to the ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release of ... new book, DOC X MD Funny Feelings translates ... style with humor and medical accuracy. The book is creatively ... answers to those age-old questions that most folks are embarrassed ... do mosquitoes bite some and not others? Why do folks ...
(Date:7/28/2014)... Cuidado Casero , an organization of Medicare ... PHC in Texas, New Mexico, New Jersey, Virginia, and Puerto ... Texas Chapter of PAM’s 2014 Gala. , North Texas ... The North Texas chapter was created by a handful of ... improving medical care for the indigent in Peru. The chapter ...
(Date:7/27/2014)... Hyaluronic Acid can hold 1,000 times ... to the power of Hyaluronic Serums. , "Hyaluronic acid ... of Sublime Beauty®. "But like collagen, it diminishes with ... improves skin moisture-retention and radiance." , Hyaluronic acid ... healthy and beautiful look. Key Ingredients in the serum ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Manufacturers of ... with organic ways to achieve a younger appearance. The ... buyer's guide to help men and women explore the ... The details that are presented in the posted guide ... price information for consumers. On drawback to some natural ...
(Date:7/27/2014)... Two new pill-only antiviral drug regimens could provide shorter, ... the majority of patients infected with hepatitis C, even ... of two studies published in The Lancet . ... which is the most common genotype in the USA, ... of the most difficult to treat. , Around 150 ...
Breaking Medicine News(10 mins):Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3
... recent issue of the journal Thorax, researchers have emphasized// ... looked into the data provided by 2401 subjects who ... and incidence of tuberculosis disease. Of the total ... skin test. The research results have showed that the ...
... is an important component of mammal’s daily life and more so ... are known to sleep for over 18 hours. However, it is ... has been reported in Nature that newborn bottlenose dolphins and killer ... Their moms manage with only a wink or two than the ...
... has published a major retrospective study that indicates // that ... infertility. ,Dr. Louise A. Brinton, of the National ... U.S. women treated for infertility between 1965 and 1988. She ... general population. The women were followed for a median of ...
... when in the womb of the mother, may have asthma ... had conducted an 11-year observation of incidence of asthma and ... significantly related to incidence of asthma in childhood. Passive smoking ... the incidence of asthma in children. ,Researchers are of ...
... (RPI), they have stated that have received the ... store in the US, for outstanding performance in the ... company with more than 1.3 million associates worldwide and ... , ,RPI is based in Jacksonville, Florida, USA ...
... who had long earlier published their findings on strong links ... up with the results from the next part of the ... ,The follow up data of the research point out ... regularly through their childhood are four times as likely to ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: